Guidelines issued by DoP for bulk drug parks

A brief guidelines for bulk drug parks and detailed guidelines will be released soon by
The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilisers, the Government of India. DoP has also announced the details of a financial assistance programme which includes grant-in-aid to three bulk drug parks with a total incentive of Rs 3000 crores for the construction of common infrastructure facilities.
Implementation of the proposed scheme will be done through a one time grant in aid and will be released in various phases for the creation of infrastructure in bulk drug to a State Implementing Agency.

The particular programme has a proposal to provide grant-in-aid to three bulk drug parks with a maximum limit of Rs 1000 crores per bulk drug park or 70 per cent of the project cost of common infrastructure facilities, as per the issued notification by Navdeep Rinwa, Joint Secretary, Department of Pharmaceuticals, .

The same notification also states that that in case of hilly regions and the North East Region, the grant-in-aid would be Rs 1000 crore per bulk drug park or 90 per cent of the project cost of common infrastructure facilities, whichever is less.

The proposed scheme would be helpful for infrastructure facilities like solvent recovery, distillation plant, central effluent treatment plant, common logistics facilities, advanced common testing centre, regulatory awareness facility centre, emergency response centre etc.

“We welcome the issued brief guidelines on bulk drug parks. The Himachal Pradesh Government is very keen on setting up the bulk drug park in the State with the help of the announced scheme by the Central Government. The State government is planning to acquire approximately 1350 acres of land, it has already identified 1000 bigha land and will be exploring the possibilities to acquire more land.” Dr Rajesh Gupta, a member of the Bulk Drug Park Committee, Himachal Pradesh and President, Himachal Drug Manufacturers Association (HDMA) told.

“We are reviewing the guidelines and will be discussing with the state industrial bodies.” said Ritu Sahay, Director-Drugs Controller, Jharkhand.

The proposal for application will be open from 2020-2021 to 2024-2025.

  • Related Posts

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch